Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter referred to as relapsed or refractory Adult T-cell Leukemia Lymphoma (ATLL)).

1. Planned registration period 3 years 2. Planned surveillance period 4 years and 6 months after a month after the approval for partial changes in the approved items is granted for relapsed or refractory ATLL

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lymphoma Arrhythmias, Cardiac Arterial Occlusive Diseases Arteriosclerosis Autonomic Nervous System Diseases Cardiovascular Diseases Cataract Confusion Coronary Artery Disease Coronary Disease Digestive System Diseases Dizziness Embolism and Thrombosis Endocrine System Diseases Eye Diseases Fatigue Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Heart Diseases Heart Failure Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhage Hypersensitivity Hypotension Hypotension, Orthostatic Hypothyroidism Immune System Diseases Immunoproliferative Disorders Infections Kidney Diseases Lens Diseases Leukemia Leukemia, Lymphoid Lung Diseases Lung Diseases, Interstitial Lymphatic Diseases Lymphoproliferative Disorders Male Urogenital Diseases Myocardial Ischemia Neoplasms Neoplasms by Histologic Type Neoplasms, Second Primary Nervous System Diseases Neurobehavioral Manifestations Neurologic Manifestations Neuromuscular Diseases Orthostatic Intolerance Pathologic Processes Pathological Conditions, Signs and Symptoms Peripheral Nervous System Diseases Precursor Cell Lymphoblastic Leukemia-Lymphoma Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Primary Dysautonomias Renal Insufficiency Respiratory Tract Diseases Seizures Sensation Disorders Signs and Symptoms Sleepiness Teratogenesis Thromboembolism Thyroid Diseases Tumor Lysis Syndrome Urogenital Diseases Urologic Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

ASO KK Iizuka Hospital

Iizuka, Fukuoka, 820-8505, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Relapsed or Refractory Adult T-cell Leukemia Lymphoma

Exclusion criteria

Treatment and study plan

Revlimid

Drug

Revlimid

Primary outcomes

Adverse Events (AEs)

Time frame: Up to approximately 4 years

Number of participants with adverse events

Sponsors and collaborators

Lead sponsor

Celgene

Industry

Registry information

Official study title

Revlimid® Capsules Drug Use-results Surveillance Relapsed or Refractory Adult T-cell Leukemia Lymphoma

Important dates

Study start: 2017
Primary completion: 2020
Study completion: 2020
First posted: Apr 4, 2017
Registry last updated: Mar 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed